Bradley J. Monk, MD, FACOG, FACS, discusses case studies in ovarian and cervical cancer. Dr. Monk explains that t
his patient is not a good candidate for secondary debulking, given the diffuse nature of her recurrent disease, and likely has carcinomatosis. Ascites is commonly associated with carcinomatosis and with bloating and impaired quality of life. Anti-VEGF therapy is particularly effective in ascites and a predictor of improved quality of life when used in the platinum-resistant patient.
CASE 1: Epithelial Ovarian Cancer
Sarah W. is a 62-year-old Caucasian woman who works as a travel agent.
In June of 2013, the patient presented with bloating and abdominal distension. Prior medical history is notable for nulliparity, and medication-controlled hypertension.
In December of 2014, the patient presents for her 6-month evaluation with rising CA-125 level, mild abdominal distension and fatigue, and inability to work.
PROs Strengthen Case for Mirvetuximab Soravtansine as SOC in FRα+ Ovarian Cancer
March 16th 2024Patient reported health-related quality of life outcomes from the phase 3 MIRASOL trial strengthen the case for mirvetuximab soravtansine as a new standard of care for patients with folate receptor-alpha positive ovarian cancer resistant to platinum chemotherapy.
Read More